Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis.
Pierre SocieAnouar BenmalekCécile CauquilEve PiekarskiIlias KounisLudivine EliahouAntoine RousseauFrancois RouzetAndoni Echaniz-LagunaDidier SamuelDavid AdamsMichel S SlamaVincent AlgalarrondoPublished in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2023)
ATTRv amyloidosis patients treated with tafamidis would present a better survival but also a faster deterioration of their cardiac and neurological statuses as compared with LT. Further studies are needed to clarify the therapeutic strategy in ATTRv amyloidosis.